TriSalus Life Sciences
TLSI
69 hedge funds and large institutions have $225M invested in TriSalus Life Sciences in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 13 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
13% more capital invested
Capital invested by funds: $198M → $225M (+$26.5M)
11.2% more ownership
Funds ownership: 80.46% → 91.67% (+11%)
1% more funds holding
Funds holding: 68 → 69 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kryger Capital
London,
United Kingdom
|
+$7.45M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$5.99M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$5.28M |
| 4 |
AC
Antara Capital
New York
|
+$4.93M |
| 5 |
Millennium Management
New York
|
+$4.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$11.4M |
| 2 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$2.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.39M |
| 4 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$2.22M |
| 5 |
AGC
Angelo Gordon & Co
New York
|
-$1.8M |
TLSI Hedge Fund Activity: Q1 2022 in Review
69 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q1 2022, worth a combined $225M — up 13% from $198M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TLSI positions and 13 closed out — a net gain of 3 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Kryger Capital, adding an estimated $7.45M. The largest seller was Aristeia Capital, exiting entirely with an estimated $11.4M sold.
- 69 institutional investors held TriSalus Life Sciences (TLSI) as of Q1 2022, up from 68 in Q4 2021.
- Funds reported $225M of TriSalus Life Sciences stock for Q1 2022, up 13% quarter-over-quarter.
- 16 funds opened new TriSalus Life Sciences positions in Q1 2022 and 13 closed out, a net change of +3 holders.
- The largest TriSalus Life Sciences buyer in Q1 2022 was Kryger Capital, an estimated $7.45M added.
- The largest TriSalus Life Sciences seller in Q1 2022 was Aristeia Capital, an estimated $11.4M sold.
Based on aggregated 13F filings for Q1 2022.